← All trials
NCT04531072
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 18, 2018
- Primary completion
- May 15, 2019
- Completion date
- Aug 15, 2019
- First posted
- Aug 28, 2020
- Last posted
- Aug 28, 2020
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institutes of Health (NIH)Lead sponsor
- National Institutes of Health (NIH)Collaborator
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- University of LagosStudy director
- University of LagosOverall official - principal investigator
- National Institutes of Health (NIH)Reponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.